Pharmaceuticals in Spain
Published: November 2012 · Publisher: MarketLine
Pharmaceuticals in Spain industry profile provides top-line qualitative and quantitative summary information including: market size (value 2007-11, and forecast to 2016).
- Description
- Table of Contents
- Ask a Question
Introduction
Pharmaceuticals in Spain industry profile provides top-line qualitative and quantitative summary information including: market size (value 2007-11, and forecast to 2016). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market. Essential resource for top-line data and analysis covering the Spain pharmaceuticals market. Includes market size data, textual and graphical analysis of market growth trends, leading companies and macroeconomic information.
Highlights
*The pharmaceuticals market consists of ethical drugs only and does not include consumer healthcare or animal healthcare.
*The Spanish pharmaceuticals market had total revenues of $19.6 billion in 2011, representing a compound annual growth rate (CAGR) of 1.6% between 2007 and 2011.
*0
*The performance of the market is forecast to decline, with an anticipated compound annual rate of change (CARC) of -1.5% for the five-year period 2011 - 2016, which is expected to drive the market to a value of $18.2 billion by the end of 2016.
Features
Save time carrying out entry-level research by identifying the size, growth, and leading players in the pharmaceuticals market in Spain
Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the pharmaceuticals market in Spain
Leading company profiles reveal details of key pharmaceuticals market players’ global operations and financial performance
Add weight to presentations and pitches by understanding the future growth prospects of the Spain pharmaceuticals market with five year forecasts
Macroeconomic indicators provide insight into general trends within the Spain economy
Key Questions Answered
What was the size of the Spain pharmaceuticals market by value in 2011?
What will be the size of the Spain pharmaceuticals market in 2016?
What factors are affecting the strength of competition in the Spain pharmaceuticals market?
How has the market performed over the last five years?
Pharmaceuticals in Spain industry profile provides top-line qualitative and quantitative summary information including: market size (value 2007-11, and forecast to 2016). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market. Essential resource for top-line data and analysis covering the Spain pharmaceuticals market. Includes market size data, textual and graphical analysis of market growth trends, leading companies and macroeconomic information.
Highlights
*The pharmaceuticals market consists of ethical drugs only and does not include consumer healthcare or animal healthcare.
*The Spanish pharmaceuticals market had total revenues of $19.6 billion in 2011, representing a compound annual growth rate (CAGR) of 1.6% between 2007 and 2011.
*0
*The performance of the market is forecast to decline, with an anticipated compound annual rate of change (CARC) of -1.5% for the five-year period 2011 - 2016, which is expected to drive the market to a value of $18.2 billion by the end of 2016.
Features
Save time carrying out entry-level research by identifying the size, growth, and leading players in the pharmaceuticals market in Spain
Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the pharmaceuticals market in Spain
Leading company profiles reveal details of key pharmaceuticals market players’ global operations and financial performance
Add weight to presentations and pitches by understanding the future growth prospects of the Spain pharmaceuticals market with five year forecasts
Macroeconomic indicators provide insight into general trends within the Spain economy
Key Questions Answered
What was the size of the Spain pharmaceuticals market by value in 2011?
What will be the size of the Spain pharmaceuticals market in 2016?
What factors are affecting the strength of competition in the Spain pharmaceuticals market?
How has the market performed over the last five years?
Copyright © FriedlNet. You may share using our tools Please don't cut content from FriedlNet and redistribute by email or post to the web.
TABLE OF CONTENTS
Executive Summary 2
Market value 2
Market value forecast 2
Geography segmentation 2
Market share 2
Market rivalry 2
Market Overview 7
Market definition 7
Market analysis 7
Market Data 8
Market value 8
Market Segmentation 9
Geography segmentation 9
Market share 10
Market Outlook 11
Market value forecast 11
Five Forces Analysis 12
Summary 12
Buyer power 13
Supplier power 15
New entrants 16
Threat of substitutes 18
Degree of rivalry 19
Leading Companies 20
Pfizer Inc. 20
GlaxoSmithKline Plc 23
Almirall S.A. 27
Macroeconomic Indicators 30
Country Data 30
Appendix 32
Methodology 32
Industry associations 33
Related research 33
LIST OF TABLES
Table 1: Spain pharmaceuticals market value: $ billion, 2007–11 8
Table 2: Spain pharmaceuticals market geography segmentation: $ billion, 2011 9
Table 3: Spain pharmaceuticals market share: % share, by value, 2011 10
Table 4: Spain pharmaceuticals market value forecast: $ billion, 2011–16 11
Table 5: Pfizer Inc.: key facts 20
Table 6: Pfizer Inc.: key financials ($) 21
Table 7: Pfizer Inc.: key financial ratios 21
Table 8: GlaxoSmithKline Plc: key facts 23
Table 9: GlaxoSmithKline Plc: key financials ($) 24
Table 10: GlaxoSmithKline Plc: key financials (L) 25
Table 11: GlaxoSmithKline Plc: key financial ratios 25
Table 12: Almirall S.A.: key facts 27
Table 13: Almirall S.A.: key financials ($) 27
Table 14: Almirall S.A.: key financials (€) 28
Table 15: Almirall S.A.: key financial ratios 28
Table 16: Spain size of population (million), 2007–11 30
Table 17: Spain gdp (constant 2000 prices, $ billion), 2007–11 30
Table 18: Spain gdp (current prices, $ billion), 2007–11 30
Table 19: Spain inflation, 2007–11 31
Table 20: Spain consumer price index (absolute), 2007–11 31
Table 21: Spain exchange rate, 2007–11 31
LIST OF FIGURES
Figure 1: Spain pharmaceuticals market value: $ billion, 2007–11 8
Figure 2: Spain pharmaceuticals market geography segmentation: % share, by value, 2011 9
Figure 3: Spain pharmaceuticals market share: % share, by value, 2011 10
Figure 4: Spain pharmaceuticals market value forecast: $ billion, 2011–16 11
Figure 5: Forces driving competition in the pharmaceuticals market in Spain, 2011 12
Figure 6: Drivers of buyer power in the pharmaceuticals market in Spain, 2011 13
Figure 7: Drivers of supplier power in the pharmaceuticals market in Spain, 2011 15
Figure 8: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Spain, 2011 16
Figure 9: Factors influencing the threat of substitutes in the pharmaceuticals market in Spain, 2011 18
Figure 10: Drivers of degree of rivalry in the pharmaceuticals market in Spain, 2011 19
Figure 11: Pfizer Inc.: revenues & profitability 22
Figure 12: Pfizer Inc.: assets & liabilities 22
Figure 13: GlaxoSmithKline Plc: revenues & profitability 25
Figure 14: GlaxoSmithKline Plc: assets & liabilities 26
Figure 15: Almirall S.A.: revenues & profitability 29
Figure 16: Almirall S.A.: assets & liabilities 29
Executive Summary 2
Market value 2
Market value forecast 2
Geography segmentation 2
Market share 2
Market rivalry 2
Market Overview 7
Market definition 7
Market analysis 7
Market Data 8
Market value 8
Market Segmentation 9
Geography segmentation 9
Market share 10
Market Outlook 11
Market value forecast 11
Five Forces Analysis 12
Summary 12
Buyer power 13
Supplier power 15
New entrants 16
Threat of substitutes 18
Degree of rivalry 19
Leading Companies 20
Pfizer Inc. 20
GlaxoSmithKline Plc 23
Almirall S.A. 27
Macroeconomic Indicators 30
Country Data 30
Appendix 32
Methodology 32
Industry associations 33
Related research 33
LIST OF TABLES
Table 1: Spain pharmaceuticals market value: $ billion, 2007–11 8
Table 2: Spain pharmaceuticals market geography segmentation: $ billion, 2011 9
Table 3: Spain pharmaceuticals market share: % share, by value, 2011 10
Table 4: Spain pharmaceuticals market value forecast: $ billion, 2011–16 11
Table 5: Pfizer Inc.: key facts 20
Table 6: Pfizer Inc.: key financials ($) 21
Table 7: Pfizer Inc.: key financial ratios 21
Table 8: GlaxoSmithKline Plc: key facts 23
Table 9: GlaxoSmithKline Plc: key financials ($) 24
Table 10: GlaxoSmithKline Plc: key financials (L) 25
Table 11: GlaxoSmithKline Plc: key financial ratios 25
Table 12: Almirall S.A.: key facts 27
Table 13: Almirall S.A.: key financials ($) 27
Table 14: Almirall S.A.: key financials (€) 28
Table 15: Almirall S.A.: key financial ratios 28
Table 16: Spain size of population (million), 2007–11 30
Table 17: Spain gdp (constant 2000 prices, $ billion), 2007–11 30
Table 18: Spain gdp (current prices, $ billion), 2007–11 30
Table 19: Spain inflation, 2007–11 31
Table 20: Spain consumer price index (absolute), 2007–11 31
Table 21: Spain exchange rate, 2007–11 31
LIST OF FIGURES
Figure 1: Spain pharmaceuticals market value: $ billion, 2007–11 8
Figure 2: Spain pharmaceuticals market geography segmentation: % share, by value, 2011 9
Figure 3: Spain pharmaceuticals market share: % share, by value, 2011 10
Figure 4: Spain pharmaceuticals market value forecast: $ billion, 2011–16 11
Figure 5: Forces driving competition in the pharmaceuticals market in Spain, 2011 12
Figure 6: Drivers of buyer power in the pharmaceuticals market in Spain, 2011 13
Figure 7: Drivers of supplier power in the pharmaceuticals market in Spain, 2011 15
Figure 8: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Spain, 2011 16
Figure 9: Factors influencing the threat of substitutes in the pharmaceuticals market in Spain, 2011 18
Figure 10: Drivers of degree of rivalry in the pharmaceuticals market in Spain, 2011 19
Figure 11: Pfizer Inc.: revenues & profitability 22
Figure 12: Pfizer Inc.: assets & liabilities 22
Figure 13: GlaxoSmithKline Plc: revenues & profitability 25
Figure 14: GlaxoSmithKline Plc: assets & liabilities 26
Figure 15: Almirall S.A.: revenues & profitability 29
Figure 16: Almirall S.A.: assets & liabilities 29
Copyright © FriedlNet. You may share using our tools Please don't cut content from FriedlNet and redistribute by email or post to the web.